Trial site
Seongnam-si Gyeonggi-do
Seongnam-si Gyeonggi-do, 463 707, South KoreaNot linked to an institution yet
- 11running trials
- 2closed trials
The trials here
What the 13 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 23 trials
- Phase 42 trials
- Phase 11 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting4 trials
- Completed2 trials
- Lead sponsor
- GlaxoSmithKline12 trials
- Tesaro, Inc.1 trial
Running trials
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT07286331· Phase 3· GlaxoSmithKline· Source
Contact: Kidong Kim (principal investigator)
Recruiting
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
NCT07177339· Phase 3· GlaxoSmithKline· Source
Contact: Ye Jin Lee (principal investigator)
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898· Phase 3· GlaxoSmithKline· Source
Contact: Yu Jung Kim (principal investigator)
Recruiting
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
NCT06847867· Phase 2· GlaxoSmithKline· Source
Contact: Soo-Mee Bang (principal investigator)
Active, not recruiting
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496· Phase 4· GlaxoSmithKline· Source
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
NCT06113198· Phase 4· GlaxoSmithKline· Source
Active, not recruiting
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
NCT04655976· Phase 2/3· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284· Phase 1· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error